AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18827610
Drug: Oral topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan (OT) with best supportive care
Trial: 2198072
Drug: Exploratory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exploratory therapy (relationship-oriented)
Trial: 2198072
Drug: Prescriptive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptive therapy (cognitive/behavioural)
Trial: 8563662
Drug: Eight sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight sessions of therapy
Trial: 2198072
Drug: 16 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 sessions of therapy
Trial: 387000
Drug: DL-phenylalanine (150-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-phenylalanine (150-200 mg/24 h)
Trial: 387000
Drug: Imipramine (150-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (150-200 mg/24 h)
Trial: 31870394
Drug: Community-based preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based preventive intervention including screening for hypertension, diabetes, and stroke, followed by referral to a mobile outreach clinic, guideline-based treatment, monthly home visits by CHWs for medication compliance, and counseling on reducing salt consumption and quitting tobacco and alcohol.
Trial: 25673557
Drug: Milk (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk (500 ml) - Male
Trial: 25673557
Drug: Carbohydrate (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (500 ml) - Female
Trial: 25673557
Drug: Carbohydrate (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (500 ml) - Male
Trial: 19317162
Drug: Longbishu Capsule,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longbishu Capsule, 0.9 g each time, taken twice a day for 4 weeks
Trial: 12573743
Drug: Compliance to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliance to prescribed radiation therapy schedule
Trial: 12573743
Drug: Recent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent treatment compliance
Trial: 2856778
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (hydrochlorothiazide + triamterene)
Trial: 18525001
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (among patients not receiving erythropoiesis-stimulating agents)
Trial: 18525001
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (among patients receiving erythropoiesis-stimulating agents)
Trial: 1996436
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron
Trial: 8360128
Drug: Mupirocin nasal
RxNorm normalized name: mupirocin Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin nasal ointment
Trial: 3121830
Drug: High heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High heparin dose (137.3 U/day) during 15-hour lipid infusion
Trial: 3121830
Drug: Low heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low heparin dose (24 U/day) infused over 24 hours
Trial: 3121830
Drug: Both heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both heparin doses at either infusion rate
Trial: 27696933
Drug: High-flavanol and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavanol and high-theobromine (HFHT) chocolate (30 grams daily for 12 weeks)
Trial: 27696933
Drug: Low-flavanol and
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flavanol and low-theobromine (LFLT) chocolate (30 grams daily for 12 weeks)
Trial: 20380782
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI) pharmacotherapy
Trial: 16060712
Drug: tretinoin emollient
RxNorm normalized name: Tretinoin Emollient Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tretinoin emollient cream 0.05%
Trial: 7822066
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg taken four times daily)
Trial: 16276136
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control (no direct thrombin inhibitors)
Trial: 12362931
Drug: Erythromycin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (800 mg per day)
Trial: 12362931
Drug: Clarithromycin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (400 mg per day)
Trial: 31346969
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with vitamin D 300,000 IU; n=46
Trial: 12747344
Drug: Oral pentazocine
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pentazocine (100 mg) plus lorazepam (1 mg)
Trial: 1619098
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) with therapeutic empathy
Trial: 1619098
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) with homework compliance
Trial: 29401473
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group writing daily events for 30 days
Trial: 16085513
Drug: Nicotine replacement,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine replacement, antidepressants, and psychological interventions
Trial: 9880175
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation treatment of 3 x 3.3 Gy
Trial: 9880175
Drug: NSAID therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID therapy (3 x 50 mg of diclofenac per day for 3 weeks)
Trial: 7973766
Drug: Single-agent vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent vinorelbine
Trial: 19323801
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg riboflavin
Trial: 19323801
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg riboflavin
Trial: 15451219
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg once a day
Trial: 19720924
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg twice a day
Trial: 11376307
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral nicorandil 3 times daily (n = 15)
Trial: 9763724
Drug: Artesunate (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (700 mg for 5 days)
Trial: 7924750
Drug: IFN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN treatment
Trial: 3047220
Drug: Sucralfate emulsion
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate emulsion (1 g four times daily)
Trial: 2035471
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg beta-carotene per day
Trial: 18928339
Drug: Aripiprazole (2-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (2-15 mg/day)
Trial: 26633622
Drug: TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitors
Trial: 18001541
Drug: Ulinastatin (UTI)
RxNorm normalized name: phenazopyridine hydrochloride Oral Tablet [UTI Relief]
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (UTI) treatment in Group A
Trial: 18001541
Drug: Ulinastatin (UTI)
RxNorm normalized name: phenazopyridine hydrochloride Oral Tablet [UTI Relief]
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (UTI) treatment in Group C
Trial: 15112008
Drug: 2.5% suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% suspension concentrate (SC) deltamethrin applied with manual compression sprayers
Trial: 15112008
Drug: 2.5% suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% suspension concentrate (SC) deltamethrin applied with power sprayers
Trial: 29794782
Drug: Intra-coronary administration
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-coronary administration of tirofiban through aspiration catheter
Trial: 29794782
Drug: Intra-coronary administration
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-coronary administration of tirofiban through guiding catheter
Trial: 27489202
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide 3% gel
Trial: 19834806
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate solutions (OSPS)
Trial: 16201292
Drug: Yaoliuan capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yaoliuan capsule
Trial: 8829933
Drug: Propofol anaesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol anaesthesia (induction: 2-3 mg kg-1, maintenance: 6-10 mg kg-1 h-1)
Trial: 6527752
Drug: disulfiram (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: disulfiram (400 mg/day) for 6 days
Trial: 2192383
Drug: placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets
Trial: 6527752
Drug: propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol (80 mg/day) for 4 weeks
Trial: 15655139
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of efalizumab weekly
Trial: 6969348
Drug: Co-trimoxazole and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole and lactobacilli preparation
Trial: 30446826
Drug: Three PVB
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three PVB injections
Trial: 30446826
Drug: Five PVB
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five PVB injections
Trial: 21346517
Drug: music and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: music and art therapy and psychomotor activity
Trial: 2042788
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion (30 ng/kg/min)
Trial: 17250535
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.005 mg/mL
Trial: 17250535
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05 mg/mL
Trial: 17250535
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.5 mg/mL
Trial: 15047241
Drug: Liposomal lurtotecan
RxNorm normalized name: Lurtotecan
DrugBank: Lurtotecan (DB12222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal lurtotecan at a dose of 2.4 mg/m(2) on Days 1 and 8 of a 21-day cycle
Trial: 9096985
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg q.d. BTS 67,582
Trial: 9096985
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg b.i.d. BTS 67,582
Trial: 9096985
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg b.i.d. BTS 67,582
Trial: 3515923
Drug: Acetaminophen alone
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen alone or in combination with oxycodone
Trial: 3515923
Drug: Acetaminophen/oxycodone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/oxycodone and lidocaine
Trial: 31133457
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (conventional subcutaneous insulin therapy)
Trial: 30387043
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 400-1200 mg/day
Trial: 24661523
Drug: Calf pulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf pulmonary surfactant (50 mg/kg) within 6 hours after admission (Treatment group 1)
Trial: 24661523
Drug: Calf pulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf pulmonary surfactant (70 mg/kg) within 6 hours after admission (Treatment group 2)
Trial: 18819261
Drug: Nifekalant hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Nifekalant (DB16008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifekalant hydrochloride (NIFE) administration after ICD shock
Trial: 18819261
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no NIFE administration)
Trial: 16115099
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body protein of E. granulosus (1 mg in 2 ml of PBS with FCA)
Trial: 11954900
Drug: Controlled-release formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release formulations (oral and transdermal) for steady pain management and fast-acting, immediate-release formulations for breakthrough pain management.
Trial: 11954900
Drug: Individualized opioid
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized opioid treatment based on drug absorption, metabolism, toxicity, and binding characteristics.
Trial: 10348790
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 14C-labeled tacrolimus (0.01 mg/kg)
Trial: 10348790
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 14C-labeled tacrolimus (0.05 mg/kg)
Trial: 6844301
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving no individual treatment, only mass education for non-high-risk individuals.
Trial: 31596444
Drug: Low-dose, low-frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose, low-frequency oral psoralen-UV-A treatment
Trial: 27267880
Drug: High-dose rotigotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rotigotine (≤8 mg/24 h for early PD or ≤16 mg/24 h for advanced PD)
Trial: 27267880
Drug: High-dose rotigotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rotigotine
Trial: 15627448
Drug: Myringotomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myringotomy with oral antibiotics (Group A)
Trial: 15627448
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics without myringotomy (Group B)
Trial: 11978141
Drug: 40% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% urea cream (Carmol 40)
Trial: 11978141
Drug: 12% ammonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% ammonium lactate lotion (Lac‐Hydrin 12%)
Trial: 2642440
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5 mg/kg CDC plus 5 mg/kg UDC
Trial: 2642440
Drug: UDC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDC alone (10 mg/kg)
Trial: 30621974
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + clopidogrel
Trial: 20350135
Drug: DRD2/ANKK1 genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRD2/ANKK1 genotype (TT vs CC)
Trial: 16006728
Drug: Prophylactic L-thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic L-thyroxine treatment
Trial: 10511942
Drug: Tranilast 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranilast 0.5% eyedrops, administered 4 times a day for 3 months
Trial: 8622101
Drug: Isepamicin 8
RxNorm normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin 8 mg/kg once daily + ceftazidime 1g twice daily
Trial: 8622101
Drug: Amikacin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin 7.5 mg/kg twice daily + ceftazidime 2g twice daily
Trial: 7299507
Drug: 525 mg
RxNorm normalized name: psyllium 525 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 525 mg of ferrous sulfate (105 mg elemental iron) and 500 mg ascorbic acid
Trial: 29510372
Drug: Daily fiber
RxNorm normalized name: Daily Fiber Sugar-Free
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily fiber intake during an 18-month weight loss intervention
Trial: 27325862
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide and methotrexate maintenance (cyclophosphamide 50 mg/day orally continuously and methotrexate 2.5 mg twice/day orally on days 1 and 2 of every week for 1 year)
Trial: 27325862
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide and methotrexate maintenance
Trial: 18296421
Drug: 1-year trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1-year trastuzumab treatment
Trial: 15756004
Drug: IL-6 levels
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 levels less than or equal to the median (4.80 pg/mL)
Trial: 15756004
Drug: IL-6 levels
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 levels above the median (4.80 pg/mL)
Trial: 15756004
Drug: IL-6 levels
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 levels at a cut point of 13.31 pg/mL
Trial: 14507747
Drug: Levocabastine hydrochloride
RxNorm normalized name: Levocabastine Hydrochloride
DrugBank: Levocabastine (DB01106)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocabastine hydrochloride 0.05% ophthalmic suspension
Trial: 8944829
Drug: Intra-arterially administered
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterially administered losartan (100-3000 ng/kg/min)
Trial: 8944829
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered losartan (50 mg once daily for 5 days)
Trial: 25688638
Drug: Curcuminoids (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids (1500 mg/day in 3 divided doses; n = 19)
Trial: 25688638
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsules (n = 21)
Trial: 25248764
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol 250/50 μg
Trial: 20619353
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 μg
Trial: 12544718
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (calcium antagonist + beta-blocker)
Trial: 10523945
Drug: Intense medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense medical therapy
Trial: 2177357
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and vindesine (maintenance chemotherapy: 2 cycles or 4 cycles)
Trial: 2177357
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and vindesine (initial chemotherapy)